Influence of folic acid, pyridoxal phosphate and cobalamin on plasma homocyst(e)ine levels and the susceptibility of low-density lipoprotein to ex-vivo oxidation.
Mild hyperhomocyst(e)inaemia is a risk factor for atherosclerotic vascular disease. In-vitro studies have shown that autooxidation of homocyst(e)ine is accompanied by the generation of oxygen radicals. This may lead to oxidative modification of low-density lipoproteins (LDL) and promote atherosclerotic vascular lesions. In male patients with peripheral arterial occlusive disease we determined fasting and post methionine load homocyst(e)ine levels by high performance liquid chromatography and the susceptibility of their LDL particles to ex-vivo oxidation by continously measuring the conjugated diene production induced by incubation with copper ions. Oxidation resistance (expressed as lag time), maximal oxidation rate, and extent of oxidation (expressed of total diene production) of LDL from patients with normal or mildly elevated homocyst(e)ine levels did not differ significantly. Folic acid, pyridoxal phosphate and cobalamin supplementation significantly decreased plasma homocyst(e)ine levels in hyperhomocyst(e)inaemic patients. This went along with a significant decrease in the extent of LDL oxidation and additionally increased HDL-cholesterol levels. The clinical relevance of these findings for the long-term course of atherosclerotic vascular disorders has to be determined by intervention studies.
Weiss
N
N
Medizinische Poliklinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität München, Pettenkoferstrasse 8a, D-80336 München, Germany. nweiss@medpoli.med.uni-muenchen.de.
Feussner
A
A
Hailer
S
S
Spengel
F A
FA
Keller
C
C
Wolfram
G
G
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000209:etiology; D005492:Folic Acid / Q000494:pharmacology*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D016491:Peripheral Vascular Diseases / Q000150:complications; D011732:Pyridoxal Phosphate / Q000494:pharmacology*; D012307:Risk Factors; D014805:Vitamin B 12 / Q000494:pharmacology*
D008077:Lipoproteins, LDL; D006710:Homocysteine; D011732:Pyridoxal Phosphate; D005492:Folic Acid; D014805:Vitamin B 12